Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Roivant Sciences Ltd. (ROIV) AI Forecast

Our AI detected a significant signal for Roivant Sciences Ltd.. Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$ROIV Bullish Signal Full forecast available
Sign Up Free

Roivant Sciences Ltd. (ROIV) Stock Forecast 2025

Roivant Sciences Ltd. (ROIV) AI Stock Price Forecast & Investment Analysis

Roivant Sciences Ltd. Stock Price Chart and Technical Analysis

Loading chart...

Roivant Sciences Ltd. (ROIV) - Comprehensive Stock Analysis & Investment Research

Deep dive into Roivant Sciences Ltd.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 8:14 p.m. (UTC)

Roivant Sciences Ltd. Investment Summary

When evaluating whether Roivant Sciences Ltd. (ROIV) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Roivant Sciences Ltd. (ROIV) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $25 billion, the company is a large-cap stock offering relative stability combined with growth potential.

Financial Performance Analysis

Our comprehensive financial analysis covers Roivant Sciences Ltd.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Roivant Sciences Ltd. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Roivant Sciences Ltd. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Roivant Sciences Ltd.

Sign Up Free
Corporate Identity

Roivant Sciences Ltd. (Stock Symbol: ROIV) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Roivant Sciences Ltd.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Roivant Sciences Ltd....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Roivant Sciences Ltd....

Unlock Full Company Profile

Get complete details about Roivant Sciences Ltd.

Sign Up Free
Revenue & Growth Analysis

Roivant Sciences Ltd. generates annual revenues of $8 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Roivant Sciences Ltd....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Roivant Sciences Ltd....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Roivant Sciences Ltd....

Unlock Financial Analysis

Get complete financial metrics for Roivant Sciences Ltd.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Roivant Sciences Ltd.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Roivant Sciences Ltd. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a large-cap market participant, the company has established significant competitive advantages and market presence. Large-cap companies typically benefit from brand recognition, operational scale, diverse revenue streams, and the financial resources to invest in research and development, marketing, and strategic acquisitions. This size category attracts substantial institutional ownership and analyst coverage.

Industry Competitive Landscape

Roivant Sciences Ltd. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-759 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 18.37 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Roivant Sciences Ltd. (ROIV) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Roivant Sciences Ltd. stock analysis.

Deep dive into Roivant Sciences Ltd.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Roivant Sciences Ltd. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Roivant Sciences Ltd.:

P/B Ratio 5.58x
Market Cap $25.28B
Book Value/Share $6.28
Revenue/Share $0.01
FCF/Share $-1.05
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Roivant Sciences Ltd. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Roivant Sciences Ltd.: An ROE of -7.3% indicates room for improvement in shareholder value creation.

ROE -7.3%
ROA -5.8%
ROIC -11.4%
Operating Margin -1996.0%
Net Margin -1062.5%
EBT Margin -1305.6%
Tax Rate -0.1%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Roivant Sciences Ltd.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Roivant Sciences Ltd.: A current ratio of 18.37 indicates strong liquidity.

Current Ratio 18.37x
D/E Ratio 0.09x
Financial Leverage 1.26x
Interest Coverage 38.3x
Working Capital $4.89B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Roivant Sciences Ltd.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Roivant Sciences Ltd.: Free cash flow of $-759M indicates cash challenges that need attention.

Operating Cash Flow -$565M
Free Cash Flow -$759M
Capital Spending -$194M
FCF/Sales -9183.5%
CapEx/Sales 2347.2%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Roivant Sciences Ltd. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Roivant Sciences Ltd.:

Fixed Assets Turnover 0.7x
Understanding Financial Statement Data

What these metrics mean: Key figures from Roivant Sciences Ltd.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Roivant Sciences Ltd.: With annual revenue of $8M, Roivant Sciences Ltd. represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $8M
Operating Income -$617M
Net Income -$328M
R&D Expense $314M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 5167%
Cash & Short-term Investments 1419%
Total Liabilities 416%
Short-term Debt 263%
Dividend & Shareholder Information
Shares Outstanding 720M
Growth Metrics (YoY)
Net Income Growth -1062.5%

Latest Roivant Sciences Ltd. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Roivant Sciences Ltd. (ROIV) stock price and investment outlook.

📰 Loading...

Roivant Sciences Ltd. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Roivant Sciences Ltd. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
AARD ██% $146M x 1.7x
ABBV ██% $454.62B 125.1x x
ABCL ██% $1.60B x 1.7x
ABEO ██% $349M 5.3x 2.4x
ABT ██% $175.49B 28.0x 3.4x
ABUS ██% $880M 5.5x 3.4x
ABVC ██% $26M x 2.4x
ABVX ██% $10.05B x x
ACAD ██% $4.25B 11.3x 3.4x
ACET ██% $79M x 0.6x
ACRS ██% $765M x 5.3x
ACRV ██% $65M x 0.7x
ACUT ██% $4M x x
ACXP ██% $6M x 0.9x
ADAG ██% $230M x 6.1x
ADCT ██% $145M x x
ADIL ██% $6M x 1.6x
ADTX ██% $4M x x
ADXN ██% $7M x x
AEON ██% $11M x x
AGIO ██% $2.15B x 1.9x
AKBA ██% $327M x 11.9x
AKTX ██% $16M x 1.1x
ALDX ██% $94M x 2.2x
ALKS ██% $8.82B 57.7x 5.0x
ALLR ██% $19M x 2.8x
ALMS ██% $3.54B x 6.2x
ALNY ██% $35.57B 113.4x 45.1x
ALT ██% $552M x 2.0x
ALXO ██% $272M x 1.8x
ALZN ██% $5M x 7.0x
AMLX ██% $1.95B x 7.2x
AMPH ██% $842M 10.6x 1.1x
AMRN ██% $287M x 0.6x
AMRX ██% $5.68B 46.5x x
ANAB ██% $1.59B x 125.1x
ANEB ██% $12M x 1.6x
ANIP ██% $1.64B 17.8x 2.9x
ANIX ██% $116M x 8.0x
ANNX ██% $807M x 4.0x
ANRO ██% $941M x 3.9x
ANTX ██% $177M x 2.2x
ANVS ██% $74M x 23.8x
APLM ██% $41M x x
APRE ██% $8M x 0.2x
APUS ██% $8M x 0.1x
APVO ██% $5M x 0.5x
AQST ██% $468M x x
ARCT ██% $165M x 0.9x
ARDX ██% $1.27B x 8.5x
ARQT ██% $3.42B x 18.0x
ARTL ██% $4M x 0.5x
ARVN ██% $524M x 1.4x
ARWR ██% $12.20B x 19.9x
ASBP ██% $9M x 2.4x
ASMB ██% $500M x 2.5x
ASND ██% $15.66B x x
ASRT ██% $151M x 2.0x
ATAI ██% $2.65B x 16.6x
ATHE ██% $85M x x
ATNM ██% $28M x 12.1x
ATOS ██% $21M x 0.7x
ATXI ██% $910K x 0.8x
AUPH ██% $1.99B 6.7x 3.5x
AVBP ██% $1.43B x 4.4x
AVIR ██% $388M x 1.7x
AVTX ██% $1.05B x 15.4x
AXIM ██% $1M x x
AXSM ██% $12.42B x 227.5x
AZTR ██% $2M x 0.2x
BBIO ██% $16.23B x x
BBOT ██% $711M x 1.9x
BCAX ██% $1.82B x 3.5x
BCTX ██% $32M x 1.3x
BCYC ██% $290M x 0.5x
BDPT ██% $10K x x
BDRX ██% $2M x x
BFRG ██% $11M x 2.3x
BFRI ██% $13M x 2.1x
BHC ██% $1.72B x x
BHST ██% $45M x 1.8x
BIOA ██% $972M x 2.6x
BIOE ██% $13M 9.7x x
BIOM ██% $510K x x
BIVI ██% $11M x 0.7x
BIXT ██% $3M x x
BLRX ██% $13M x x
BLTE ██% $6.10B x 7.9x
BMEA ██% $91M x 4.9x
BMRN ██% $11.38B 42.3x 1.8x
BMY ██% $125.36B 17.2x 6.3x
BNTC ██% $396M x 2.2x
BOLD ██% $56M x 0.7x
BOLT ██% $7M x 0.4x
BPTH ██% $2M x x
BQST ██% $2M x x
BRNS ██% $25M x 0.4x
BSPK ██% $10K x x
BTAI ██% $24M x x
BYSI ██% $44M x x
CALC ██% $11M x x
CANF ██% $7M x 1.2x
CAPR ██% $1.14B x 4.1x
CATX ██% $336M x 1.0x
CBIO ██% $629M x 6.2x
CDT ██% $2M x x
CING ██% $62M x 3.3x
CLCS ██% $65M x x
CLNN ██% $65M x x
CLRB ██% $20M x 5.9x
CLSDQ ██% $1M x x
CLYM ██% $731M x 4.9x
CMMB ██% $10M x 0.8x
CMND ██% $2M x x
CMPS ██% $1.58B x 4.8x
CNBX ██% N/A x x
CNSP ██% $8M x 111.8x
CNTA ██% $6.27B x 12.9x
CNTB ██% $138M x 3.2x
CNTX ██% $54M x 1.0x
COCP ██% $13M x 3.1x
COGT ██% $6.87B x 11.3x
COLL ██% $1.15B 15.4x 3.7x
CORT ██% $10.09B 213.2x 15.8x
COYA ██% $103M x 2.1x
CPHI ██% $75M x 2.0x
CPIX ██% $102M x 4.7x
CPMD ██% $1M x x
CPRX ██% $3.85B 17.4x 3.8x
CRBP ██% $165M x 1.3x
CRMD ██% $631M 3.5x 1.4x
CRNX ██% $8.81B x 6.9x
CRVO ██% $25M x 2.3x
CRVS ██% $1.15B x 4.8x
CTMX ██% $725M x 2.3x
CTNM ██% $537M x 2.2x
CTOR ██% $54M x 1.5x
CTTH ██% $4M x 5.3x
CTXR ██% $14M x 0.2x
CUE ██% $136M x 6.3x
CURX ██% $6M x 0.7x
CVKD ██% $6M x 3.5x
CVSI ██% $4M x 2.6x
CYCN ██% $15M x 2.3x
CYDY ██% $285M x x
CYPH ██% $62M x 0.7x
CYRX ██% $759M 9.5x 1.5x
CYTK ██% $11.12B x x
DARE ██% $18M x 25.0x
DCOY ██% $3M x 0.7x
DERM ██% $180M x 5.8x
DMAC ██% $367M x 7.8x
DMRA ██% $1.83B x 3.6x
DNTH ██% $5.72B x 4.8x
DRMA ██% $5M x 0.8x
DRUG ██% $700M x x
DSGN ██% $726M x 3.3x
DWTX ██% $51M x 0.6x
DYN ██% $3.95B x 4.6x
EBS ██% $388M x 0.7x
EDSA ██% $50M x 4.9x
ELAB ██% $4M x 0.3x
ELAN ██% $12.37B x 1.9x
ELDN ██% $284M x 6.3x
ELTP ██% $409M 9.1x 4.1x
ELTX ██% $83M x x
ELVN ██% $3.77B x 8.3x
EMMA ██% $820K x x
ENLV ██% $73M 0.0x 0.0x
ENSC ██% $4M x x
ENTA ██% $376M x 3.2x
ENVB ██% $5M x 1.1x
EOLS ██% $404M x x
EPRX ██% $412M x 5.0x
EQ ██% $161M x 2.7x
ERAS ██% $6.01B x 15.3x
ERNA ██% $5M x 0.7x
ESPR ██% $799M x x
ETON ██% $1.21B x 39.5x
ETST ██% $35M 7.2x 5.0x
EVFM ██% $1M x x
EVMN ██% $408M x 1.3x
EWTX ██% $4.45B x 9.0x
FBIO ██% $114M 0.9x 0.7x
FBLG ██% $4M x 1.5x
FBRX ██% $1.57B x 37.2x
FHTX ██% $298M x x
FLNA ██% $45M x 0.7x
FTH ██% $716M x x
FULC ██% $250M x 0.8x
GALT ██% $227M x x
GANX ██% $77M x 5.5x
GCAN ██% $260K x x
GDTC ██% $10M x x
GERN ██% $963M x 4.2x
GHRS ██% $1.73B x x
GLMD ██% $3M x 0.2x
GLSI ██% $193M x 36.7x
GNLX ██% $133M x 5.8x
GNPX ██% $4M x 0.2x
GOSS ██% $70M x x
GOVX ██% $4M x 8.9x
GPCR ██% $3.61B x 2.5x
GRCE ██% $39M x 0.6x
GRI ██% $3M x 0.3x
GRTX ██% $3.38B 22.7x 4646.0x
GSK ██% $101.62B x x
GTBP ██% $12M x 1.6x
GYRE ██% $670M x 6.6x
HCM ██% $1.88B 2.1x 1.5x
HCWB ██% $4M x 0.7x
HELP ██% $479M x x
HEPA ██% $1M x 0.7x
HIND ██% $15M x 2.2x
HOOK ██% $14M x 0.4x
HOWL ██% $17M x 1.4x
HRMY ██% $2.07B 14.2x 2.3x
HRTX ██% $87M x 9.6x
HSTC ██% $99M x 79.9x
HURA ██% $137M x 5.9x
HYFT ██% $55M x x
HYPD ██% $40M x 0.7x
IBIO ██% $70M x 0.9x
IBO ██% $46M x 4.0x
IDYA ██% $3.22B x 3.4x
IFRX ██% $255M x x
IGC ██% $27M x 4.4x
IMMP ██% $57M x x
IMMX ██% $626M x 7.4x
IMNM ██% $2.49B x 4.2x
IMNN ██% $6M x 1.8x
IMRN ██% $9M x x
IMRX ██% $284M x 1.4x
IMUX ██% $195M x 1.3x
INBP ██% $5M x 0.3x
INDP ██% $369M x 295.8x
INDV ██% $5.02B 19.9x x
INM ██% $10M x 1.4x
INO ██% $84M x 13.8x
INSM ██% $23.26B x 33.0x
INTI ██% $15M x x
INVA ██% $1.58B 3.1x 1.2x
IOBTQ ██% $70K x 0.1x
IONS ██% $9.27B x 18.9x
IRD ██% $241M x x
IRON ██% $2.87B x 4.2x
IRWD ██% $624M 6.1x x
ISCO ██% $2M x x
IVA ██% $1.07B x x
IXHL ██% $38M x 0.5x
JAGX ██% $5M x x
JANX ██% $957M x 1.0x
JAZZ ██% $15.78B 534.9x 3.5x
JBIO ██% $1.19B x 4.0x
JNJ ██% $624.17B 29.7x 7.4x
JUNS ██% $6M x x
KALA ██% $11M x 1.1x
KALV ██% $1.38B x x
KAPA ██% $6M x 1.2x
KAYS ██% $140K x x
KMDA ██% $401M x x
KNSA ██% $4.82B 66.0x 8.0x
KPRX ██% $10M x 0.7x
KPTI ██% $160M x x
KROS ██% $200M x 0.7x
KRRO ██% $166M x 1.4x
KTTA ██% $16M x 0.3x
KURA ██% $928M x 8.6x
KYNB ██% $29M 0.2x x
LAB ██% $343M 4.4x 0.6x
LBRX ██% $993M x 2.6x
LEGN ██% $4.55B x x
LEXX ██% $14M x 3.0x
LFCR ██% $166M x x
LFVN ██% $79M 10.0x 2.4x
LGND ██% $6.05B 39.4x 6.1x
LGVN ██% $19M x 1.2x
LIANY ██% $12M x 0.1x
LIFD ██% $3M x 0.4x
LIPO ██% $150K x 0.1x
LITS ██% $35M x 0.6x
LIXT ██% $120M x 15.2x
LKFT ██% $1.85B x x
LLY ██% $1.07T 42.4x 34.4x
LNAI ██% $11M x x
LPCN ██% $16M x 0.7x
LQDA ██% $7.86B 352.5x 72.4x
LRMR ██% $403M x 2.6x
LSTA ██% $19M x 1.8x
LTRN ██% $32M x 9.4x
LXRX ██% $943M x 4.7x
LYEL ██% $298M x 1.1x
MAIA ██% $78M x 2.8x
MANE ██% $4.84B x 12.4x
MBIO ██% $4M x 0.5x
MBRX ██% $16M x 1.0x
MBX ██% $3.02B x 6.9x
MCRB ██% $50M x 1.9x
MDCX ██% $22M x 16.4x
MDGL ██% $12.52B x 23.0x
MGNX ██% $255M x 12.0x
MIRA ██% $39M x 4.2x
MIRM ██% $6.97B x 28.7x
MIST ██% $141M x 3.9x
MLTX ██% $1.62B x 6.4x
MLYS ██% $2.23B x 3.5x
MNKD ██% $1.20B x x
MNOV ██% $64M x 1.6x
MNPR ██% $708M x 5.2x
MPLT ██% $1.59B x 4.0x
MREO ██% $46M x 1.4x
MRK ██% $322.55B 36.1x 7.0x
MRKR ██% $20M x 1.5x
MRVI ██% $2.60B x 12.3x
MSLE ██% $200M x x
MTNB ██% $2M x 0.5x
MTVA ██% $8M x 0.9x
NAMS ██% $3.56B x 5.4x
NATR ██% $360M 18.1x 2.2x
NBP ██% $205M x 0.8x
NBTX ██% $1.91B x x
NCEL ██% $20M x 37.7x
NCNA ██% $6M x x
NERV ██% $195M x x
NEUP ██% $21M x 0.7x
NGNE ██% $710M x 3.0x
NIKA ██% $806M x x
NKTR ██% $2.34B x 4.1x
NKTX ██% $171M x 0.6x
NMAD ██% $89M x 11.2x
NNVC ██% $33M x 3.6x
NRIX ██% $2.46B x 6.1x
NRSN ██% $24M x x
NRXP ██% $176M x x
NSRX ██% $36M x 13.1x
NTHI ██% $90M x x
NUVB ██% $2.25B x 7.0x
NUVL ██% $9.75B x 8.3x
NVCT ██% $635M x 44.7x
NVS ██% $297.94B x x
NWBO ██% $273M x x
NXTC ██% $17M x 0.6x
NXTS ██% $3M x 0.2x
OCUL ██% $1.89B x 3.2x
OGEN ██% $2M x 0.4x
OGI ██% $130M x x
OGN ██% $3.56B 14.5x 3.9x
OKUR ██% $170M x 0.9x
OLMA ██% $1.03B x 2.1x
OMER ██% $740M 8.6x x
ONC ██% $33.90B 66.1x 7.1x
ONCO ██% $3M x 0.3x
ONCY ██% $99M x x
OPK ██% $888M x 0.7x
ORGO ██% $313M 115.0x 1.3x
ORIC ██% $1.13B x 2.7x
ORKA ██% $5.55B x 11.4x
ORMP ██% $170M 1.6x 0.7x
OSTX ██% $61M x x
OTLC ██% $13M x 0.1x
OVID ██% $401M x 2.0x
OWPC ██% $110K x x
PAHC ██% $1.38B 14.5x 3.8x
PBH ██% $2.37B 12.5x 1.3x
PBM ██% $11M x x
PBYI ██% $408M 16.7x 3.2x
PCRX ██% $1.02B 198.4x 1.6x
PCSA ██% $8M x 3.0x
PCYN ██% $2M x 1.0x
PDSB ██% $39M x 10.1x
PEPG ██% $145M x 1.1x
PFE ██% $142.33B 19.0x 1.6x
PGEN ██% $1.97B x 97.4x
PHAT ██% $922M x x
PHIO ██% $12M x 0.8x
PHVS ██% $2.32B x x
PKTX ██% $3M x 10.3x
PLRX ██% $67M x 0.4x
PLYX ██% $100M x 40.2x
PMHS ██% $2M x x
PMN ██% $113M x 1.9x
PMVP ██% $71M x 0.8x
PPBT ██% $1M x x
PPCB ██% $3M x 0.3x
PRAX ██% $8.98B x 6.4x
PRFX ██% $4M x 0.4x
PRGO ██% $1.39B x 0.6x
PRLD ██% $324M x 5.4x
PRPH ██% $840K x 0.1x
PRQR ██% $253M x x
PRTA ██% $453M x 1.5x
PTCT ██% $6.50B x x
PTGX ██% $8.70B x 13.3x
PTIX ██% $420K x x
PTN ██% $14M x 1.4x
PTPI ██% $170K 0.0x 0.1x
PULM ██% $6M x 1.8x
PVCT ██% $26M x x
PVLA ██% $2.05B x 8.8x
PYXS ██% $168M x 5.4x
QNRX ██% $9M x 1.0x
QNTM ██% $21M x x
QTTB ██% $457M 13.7x 9.9x
QUCY ██% $25M x 5.5x
QURE ██% $2.49B x 16.6x
RADX ██% $34M x x
RANI ██% $122M x 4.3x
RAPP ██% $1.98B x 4.2x
RARE ██% $2.66B x x
RCKT ██% $358M x 1.5x
RCUS ██% $3.67B x 7.0x
RDY ██% $9.85B x x
REGN ██% $67.80B 15.3x 2.2x
REVB ██% $4M x 0.3x
RFL ██% $118M x 1.6x
RGBP ██% $80K x x
RIGL ██% $678M 1.9x 1.7x
RKTO ██% $19M x 4.5x
RLMD ██% $546M x 2.5x
RLYB ██% $87M x 1.7x
RMHI ██% $25M x x
RMTI ██% $27M x 0.7x
RNAC ██% $229M x x
RNAZ ██% $7M x 5.5x
RNTX ██% $68M x 5.9x
RNXT ██% $43M x 3.8x
ROIV ██% $25.28B x 5.6x
RPRX ██% $33.99B 41.1x 4.9x
RTEZ ██% $1.93B x x
RVPH ██% $6M x 0.4x
RVRC ██% $101M x 16.5x
RYTM ██% $7.03B x 57.2x
RZLT ██% $466M x 4.0x
SBFM ██% $3M x 0.1x
SCNX ██% $16M x 0.2x
SCYX ██% $290M x 7.0x
SDEV ██% $30M 0.1x 0.2x
SDGR ██% $1.12B x 3.6x
SEPN ██% $1.50B x 4.0x
SER ██% $31M x 1.8x
SGMT ██% $433M x 4.2x
SHPH ██% $2M x 0.5x
SIGA ██% $228M 11.3x 1.5x
SILO ██% $5M x 0.9x
SION ██% $2.14B x 7.4x
SKVI ██% $1M x x
SKYE ██% $24M x 2.6x
SLGL ██% $261M x 11.5x
SLN ██% $541M x 11.0x
SLS ██% $2.24B x 20.8x
SMMT ██% $11.88B x 18.9x
SMNR ██% $157M x x
SNDX ██% $1.90B x 45.6x
SNGX ██% $5M x 1.8x
SNSE ██% $31M x x
SNY ██% $106.10B x x
SPRB ██% $124M x 3.6x
SPRC ██% $3M x x
SPRO ██% $69M 4.5x 1.3x
SPRY ██% $596M x 9.7x
SRPT ██% $1.73B 26.6x 1.2x
STOK ██% $1.89B x 4.8x
STTK ██% $702M x 7.3x
SUPN ██% $2.75B x 2.6x
SVRA ██% $1.16B x 6.6x
SXTP ██% $4M x 0.9x
SYBX ██% $8M x 0.6x
SYRE ██% $7.88B x 11.7x
TAK ██% $55.84B x x
TBPH ██% $870M 7.6x 3.0x
TCRT ██% $5M x 3.5x
TELO ██% $82M x 16.5x
TENX ██% $416M x 3.6x
TEVA ██% $36.16B 23.1x 4.4x
TGTX ██% $8.68B 18.8x 14.9x
TLPH ██% $65M x 3.5x
TLX ██% $3.38B x x
TNGX ██% $4.37B x 11.2x
TNXP ██% $165M x 0.7x
TOVX ██% $10M x 0.7x
TPST ██% $15M x 18.3x
TRDA ██% $236M x 0.9x
TRVI ██% $2.31B x 13.4x
TTRX ██% $243M x 39.7x
TVRD ██% $23M x 1.6x
TVTX ██% $5.27B x 53.4x
TXMD ██% $24M 132.6x 0.9x
TYRA ██% $1.89B x 4.9x
UNCY ██% $131M x 3.5x
UPB ██% $344M x 1.1x
URGN ██% $1.99B x x
UTHR ██% $26.39B 20.5x 4.5x
VBIO ██% $900K x 0.1x
VCNX ██% $3M x x
VERA ██% $2.54B x 5.1x
VGLS ██% $240K x x
VICP ██% $47M x x
VKTX ██% $4.04B x 8.1x
VNDA ██% $319M x 1.1x
VRCA ██% $87M x 5.4x
VRDN ██% $2.05B x 3.2x
VREOD ██% $491M x 1.7x
VREOF ██% $491M x 1.7x
VRTX ██% $122.36B 28.2x 6.3x
VSTM ██% $551M x 6.7x
VTGN ██% $9M x 0.2x
VTRS ██% $20.28B x 1.4x
VYNE ██% $17M x 0.7x
WHWK ██% $174M x 1.5x
WVE ██% $1.15B x 2.2x
XBIO ██% $6M x 0.8x
XBIT ██% $69M x 0.5x
XCUR ██% $11M x 5.2x
XENE ██% $6.28B x 4.7x
XERS ██% $1.45B 120.6x 111.3x
XLO ██% $58M x 0.8x
XNCR ██% $1.48B x 2.9x
XOMA ██% $710M 21.0x 7.7x
XTLB ██% $7M x x
ZBIO ██% $2.07B x 6.2x
ZLAB ██% $2.09B x 3.2x
ZNTL ██% $321M x 1.8x
ZTS ██% $32.38B 12.3x 10.0x
ZVRA ██% $571M 4.6x 2.8x
ZVSA ██% $940K x x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Roivant Sciences Ltd. Stock Forecast

How accurate are Roivant Sciences Ltd. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for ROIV predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Roivant Sciences Ltd. stock price forecasts?

Our analysis considers Roivant Sciences Ltd.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Roivant Sciences Ltd. a good investment in 2025?

Based on our AI analysis, Roivant Sciences Ltd. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Roivant Sciences Ltd. forecasts updated?

Roivant Sciences Ltd. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Roivant Sciences Ltd.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...